Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down's syndrome

NeuroMolecular Medicine

Volumn 16, Issue 2, 2014, Pages 510-516

  Portelius, Erik ^a   Hölttä, Mikko ^a   Soininen, Hilkka ^b,c   Bjerke, Maria ^a   Zetterberg, Henrik ^a,d   Westerlund, Anni ^a   Herukka, Sanna Kaisa ^b,c   Blennow, Kaj ^a   Mattsson, Niklas ^a,e,f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid precursor like protein 1; Amyloid ; Cerebrospinal fluid; Down's syndrome; Mass spectrometry

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-28]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR LIKE PROTEIN 1 BETA 25; AMYLOID PRECURSOR LIKE PROTEIN 1 BETA 27; AMYLOID PRECURSOR LIKE PROTEIN 1 BETA 28; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN 1; PLASMIN; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-28); AMYLOID BETA-PROTEIN (1-42); APLP1 PROTEIN, HUMAN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYBRID IMMUNOAFFINITY MASS SPECTROMETRY; IN VITRO STUDY; MALE; MASS SPECTROMETRY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN LOCALIZATION; PROTEIN METABOLISM; ADULT; AMINO ACID SEQUENCE; CEREBROSPINAL FLUID; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; PROTEIN PROCESSING; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

ADULT; AGE FACTORS; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; DOWN SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIN; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84901259327     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-014-8302-1     Document Type: Article

References (26)

1. Anckarsater, R., Vasic, N., Jideus, L., Kristiansson, M., Zetterberg, H., Blennow, K., et al. (2007). Cerebrospinal fluid protein reactions during non-neurological surgery. Acta Neurologica Scandinavica, 115(4), 254-259. doi: 10.1111/j.1600-0404.2006.00741.x.
2. Andreasson, U., Portelius, E., Andersson, M. E., Blennow, K., & Zetterberg, H. (2007). Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomarkers in Medicine, 1(1), 59-78. doi: 10.2217/17520363.1.1.59.
3. Blennow, K., de Leon, M. J., & Zetterberg, H. (2006). Alzheimer's disease. Lancet, 368(9533), 387-403.
4. Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews. Neurology, 6(3), 131-144. doi: 10.1038/nrneurol.2010.4.
5. Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., Richter, R. W., et al. (2012). Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Archives of Neurology, 69(11), 1430-1440. doi: 10.1001/archneurol.2012.2194.
6. Goldgaber, D., Lerman, M. I., McBride, O. W., Saffiotti, U., & Gajdusek, D. C. (1987). Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science, 235(4791), 877-880.
7. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., et al. (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature, 325(6106), 733-736.
8. Karran, E., Mercken, M., & De Strooper, B. (2011). The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nature Reviews. Drug Discovery, 10(9), 698-712. doi: 10.1038/nrd3505.
9. Ledesma, M. D., Da Silva, J. S., Crassaerts, K., Delacourte, A., De Strooper, B., & Dotti, C. G. (2000). Brain plasmin enhances APPα-cleavage and Aβ degradation and is reduced in Alzheimer's disease brains. EMBO Reports, 1(6), 530-535. doi: 10.1093/embo-reports/kvd107.
10. Leverenz, J. B., & Raskind, M. A. (1998). Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Experimental Neurology, 150(2), 296-304. doi: 10.1006/exnr.1997.6777.
11. Lewczuk, P., Esselmann, H., Meyer, M., Wollscheid, V., Neumann, M., Otto, M., et al. (2003). The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: Evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Communications in Mass Spectrometry, 17(12), 1291-1296.
12. Mattsson, N., Rajendran, L., Zetterberg, H., Gustavsson, M., Andreasson, U., Olsson, M., et al. (2012). BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system. PLoS One, 7(2), e31084. doi: 10.1371/journal.pone.0031084.
13. Portelius, E., Andreasson, U., Ringman, J. M., Buerger, K., Daborg, J., Buchhave, P., et al. (2010a). Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Molecular Neurodegeneration, 5, 2. doi: 10.1186/1750-1326-5-2.
14. Portelius, E., Dean, R. A., Gustavsson, M. K., Andreasson, U., Zetterberg, H., Siemers, E., et al. (2010b). A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease. Alzheimer's Research and Therapy, 2(2), 7. doi: 10.1186/alzrt30.
15. Portelius, E., Mattsson, N., Andreasson, U., Blennow, K., & Zetterberg, H. (2011a). Novel Aβ isoforms in Alzheimer's disease - their role in diagnosis and treatment. Current Pharmaceutical Design, 17(25), 2594-2602.
16. Portelius, E., Price, E., Brinkmalm, G., Stiteler, M., Olsson, M., Persson, R., et al. (2011b). A novel pathway for amyloid precursor protein processing. Neurobiology of Aging, 32(6), 1090-1098. doi: 10.1016/j. neurobiolaging.2009.06.002.
17. Portelius, E., Soininen, S., Andreasson, U., Zetterberg, H., Persson, R., Karlsson, G., et al. (2014). Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid. Neurodegenerative Diseases (accepted).
18. Portelius, E., Tran, A. J., Andreasson, U., Persson, R., Brinkmalm, G., Zetterberg, H., et al. (2007). Characterization of amyloid β peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. Journal of Proteome Research, 6(11), 4433-4439. doi: 10.1021/pr0703627.
19. Prasher, V. P., Farrer, M. J., Kessling, A. M., Fisher, E. M., West, R. J., Barber, P. C., et al. (1998). Molecular mapping of Alzheimer-type dementia in Down's syndrome. Annals of Neurology, 43(3), 380-383. doi: 10.1002/ana.410430316.
20. Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., et al. (2012). Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurology, 11(12), 1048-1056. doi: 10.1016/S1474-4422(12)70228-4.
21. Tamaoka, A., Sekijima, Y., Matsuno, S., Tokuda, T., Shoji, S., & Ikeda, S. I. (1999). Amyloid beta protein species in cerebrospinal fluid and in brain from patients with Down's syndrome. Annals of Neurology, 46(6), 933.
22. Tapiola, T., Soininen, H., & Pirttila, T. (2001). CSF tau and Aβ42 levels in patients with Down's syndrome. Neurology, 56(7), 979-980.
23. Tucker, H. M., Kihiko, M., Caldwell, J. N., Wright, S., Kawarabayashi, T., Price, D., et al. (2000). The plasmin system is induced by and degrades amyloid-β aggregates. Journal of Neuroscience, 20(11), 3937-3946.
24. Van Nostrand, W. E., & Porter, M. (1999). Plasmin cleavage of the amyloid β-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry, 38(35), 11570-11576.
25. Wasco, W., Brook, J. D., & Tanzi, R. E. (1993). The amyloid precursor-like protein (APLP) gene maps to the long arm of human chromosome 19. Genomics, 15(1), 237-239. doi: 10.1006/geno.1993.1047.
26. Yanagida, K., Okochi, M., Tagami, S., Nakayama, T., Kodama, T. S., Nishitomi, K., et al. (2009). The 28-amino acid form of an APLP1-derived Aβ-like peptide is a surrogate marker for Aβ42 production in the central nervous system. EMBO Mol Med, 1(4), 223-235. doi: 10.1002/emmm. 200900026.